Amyopathic dermatomyositis combined with peripheral neuropathy.
Miyake Z, Ishii A, Okiyama N, Tamaoka A.
BMJ Case Rep. 2020 Nov 30;13(11):e237250. doi: 10.1136/bcr-2020-237250.
Neurological Adverse Reactions to SARS-CoV-2 Vaccines.
Finsterer J.
Clin Psychopharmacol Neurosci. 2023 May 30;21(2):222-239. doi: 10.9758/cpn.2023.21.2.222.
Neurology of inflammatory bowel disease.
Ferro JM, Oliveira Santos M.
J Neurol Sci. 2021 May 15;424:117426. doi: 10.1016/j.jns.2021.117426. Epub 2021 Mar 27.
Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee.
Tavee J, Brannagan TH 3rd, Lenihan MW, Muppidi S, Kellermeyer L, D Donofrio P; AANEM.
Muscle Nerve. 2023 Oct;68(4):356-374. doi: 10.1002/mus.27922. Epub 2023 Jul 11.
[Peripheral nervous system immunological disorder].
Erazo Torricelli R.
Medicina (B Aires). 2018;78 Suppl 2:82-87.
Increased Epidermal Nerve Growth Factor without Small-Fiber Neuropathy in Dermatomyositis.
Wong LS, Lee CH, Yen YT.
Int J Mol Sci. 2022 Aug 12;23(16):9030. doi: 10.3390/ijms23169030.
Neuromuscular complications of hematopoietic stem cell transplantation.
Ruzhansky KM, Brannagan TH 3rd.
Muscle Nerve. 2015 Oct;52(4):480-7. doi: 10.1002/mus.24724. Epub 2015 Aug 19.
Intravenous immunoglobulin therapy.
Chapel H.
QJM. 1996 Sep;89(9):641-3. doi: 10.1093/qjmed/89.9.641.
Immunoglobulin Treatment in Neuromuscular Medicine.
Burakgazi AZ.
J Clin Neuromuscul Dis. 2019 Jun;20(4):182-193. doi: 10.1097/CND.0000000000000235.
Dermatomyositis-associated sensory neuropathy: a unifying pathogenic hypothesis.
Nguyen TP, Bangert C, Biliciler S, Athar P, Sheikh K.
J Clin Neuromuscul Dis. 2014 Sep;16(1):7-11. doi: 10.1097/CND.0000000000000048.
